IBRX NASDAQ
ImmunityBio, Inc.
1W: -1.6%
1M: +1.3%
3M: +26.4%
YTD: +327.2%
1Y: +249.4%
3Y: +563.9%
5Y: -5.9%
$8.63
+0.82 (+10.50%)
Weekly Expected Move ±11.1%
$6
$7
$8
$9
$10
Credit Risk of going bust: higher than 77% of companies Debt: 8.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.14 (down 98%), ImmunityBio, Inc. would be worth roughly what it owes.
Total debt $813.1M against a stock market value of $9.15B.
Distance to default 2.84 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $387.2M (short-term plus half of long-term), stock volatility 101.5%; Altman Z'' -30.40. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.14 (down 98%), ImmunityBio, Inc. would be worth roughly what it owes.
Total debt $813.1M against a stock market value of $9.15B.
Distance to default 2.84 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $387.2M (short-term plus half of long-term), stock volatility 101.5%; Altman Z'' -30.40. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
18 relationships15
As Filer
counterparties named
3
As Counterparty
mentioned by others
4
Rel. Types
2021-05-03
Earliest Filing
2025-12-29
Latest Filing
partner: 7
investor: 5
acquirer: 2
supplier: 1
Counterparties (Filed by IBRX)
15 relationshipsCompanies named in IBRX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Jefferies LLC | JEF | partner | Sales agent for the at-the-market offering program | 2025-12-29 | View |
| Infinity SA LLC | INR | investor | Purchaser Agent for revenue interest purchase agreement | 2024-01-02 | View |
| Oberland Capital Management LLC | — | investor | Affiliate of Purchaser Agent | 2024-01-02 | View |
| NantMobile, LLC | — | investor | Participated in a stock purchase agreement exchanging existing convertible notes for common stock. | 2023-09-11 | View |
| NantCancerStemCell, LLC | — | investor | Participated in a stock purchase agreement exchanging existing convertible notes for common stock. | 2023-09-11 | View |
| NantWorks, LLC | — | investor | Holder of convertible promissory note converted to equity | 2022-12-12 | View |
| Athenex, Inc. | — | acquirer | Seller of rights and leasehold interest in the Dunkirk Facility to ImmunityBio, Inc. | 2022-02-15 | View |
| Fort Schuyler Management Corporation | — | partner | Landlord under the Lease Agreement for the Dunkirk Facility. | 2022-02-15 | View |
| Empire State Development | — | partner | New York State Urban Development Corporation providing consents and grants. | 2022-02-15 | View |
| County of Chautauqua Industrial Development Agency | — | partner | Agency providing consents and tax savings for the Dunkirk Facility. | 2022-02-15 | View |
| Athenex, Inc. | — | acquirer | Seller of rights and obligations for the Dunkirk Facility manufacturing lease and agreements to ImmunityBio, Inc. | 2022-01-12 | View |
| 420 Nash, LLC | — | partner | Commercial lease agreement for warehousing and storage property | 2021-09-27 | View |
| Nant Capital | — | partner | Purchase agreement and leaseback for real property | 2021-09-27 | View |
| 605 Nash, LLC | — | supplier | Lease counterparty for facility expansion and manufacturing premises | 2021-05-28 | View |
| Jefferies LLC | JEF | partner | Sales agent for the Open Market Sale Agreement | 2021-05-03 | View |
Mentioned As Counterparty
3 mentionsOther companies that named IBRX in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| HCWB HCW Biologics Inc. | partner | Parent company of Altor and NantCell, counterparty in settlement agreement | 2024-07-18 | View |
| LADX LadRx Corp | partner | Licensee under the License Agreement referenced in the filing | 2023-06-26 | View |
| XOMAP XOMA Corp | partner | Counterparty in the Exclusive License Agreement whose milestone payments were acquired by XOMA | 2023-06-22 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-14 | Regulation FD; Exhibits | View | |
| 2026-08-04 | Earnings Release; Exhibits | View | |
| 2026-07-30 | Regulation FD; Exhibits | View | |
| 2026-06-10 | Shareholder Vote; Exhibits | View | |
| 2026-05-18 | Material Agreement; Regulation FD; Exhibits | Agreement | View |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-04-09 | Earnings Release; Exhibits | View | |
| 2026-04-06 | Regulation FD; Exhibits | View | |
| 2026-03-31 | Material Agreement; Financial Obligation; Regulation FD; Other Events; Exhibits | Agreement | View |
| 2026-02-23 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-02-18 | Other Events; Financial Statements and Exhibits | View | |
| 2026-01-26 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2026-01-15 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-14 | Other Events; Financial Statements and Exhibits | View | |
| 2025-12-29 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-12-15 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-12-12 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-08 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR